About
Powerhouse Biology, Inc. is an early-stage biotech based in San Carlos, California, developing precision protein and peptide therapeutics targeting mitochondrial dysfunction, with applications in cell manufacturing yields, cell-therapy efficacy and late-onset diseases such as Parkinson's and Alzheimer's.
Capital graph
Founders / team· 2
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Powerhouse Biology
Powerhouse Biology, Inc. is an early-stage biotech based in San Carlos, California, developing precision protein and peptide therapeutics targeting mitochondrial dysfunction, with applications in cell manufacturing yields, cell-therapy efficacy and late-onset diseases such as Parkinson's and Alzheimer's.
—
United States
BusinessLatest roundTotal raisedDate- NewLimit
Develops longevity drugs that reprogram epigenetic marks to extend human healthspan
Series C · $565M · 2026-06 · Valuation $3.1B
$565MValuation $3.1B - TwoStep Therapeutics
Targeted peptide-drug conjugates and radioligand therapies for solid tumors
Series A · $71M · 2026-09
$71M - Astromech
AI models trained on cross-species genomic and evolutionary data to predict how biological systems evolve and where they are vulnerable
Undisclosed · $60M · 2026-08 · Valuation $3.8B
$60MValuation $3.8B
China
BusinessLatest roundTotal raisedDate- Convergen
TRIM21-based TrimTAC targeted protein degradation platform for therapies clearing pathological protein aggregates; pipeline focused on neurodegenerative and autoimmune diseases
Seed · $25M · 2026-08
$25M - Syneron Bio
AI-driven synthetic peptide drug developer focused on a pipeline of next-generation synthetic peptide and protein drugs
Series B · $280M · 2026-04
$280M - Levinthal Biotech
AI protein design services, with the proprietary all-atom protein design platform Pallatom
Series A · $14M · 2025-12
$14M
Europe
BusinessLatest roundTotal raisedDate- Basecamp Research
Trains the EDEN foundation model on proprietary biodiversity genomic data and uses AI to design proteins and in vivo cell therapies
Series C · $200M · 2026-09
$200M - Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds its own therapeutic pipeline and conducts joint R&D with large pharmaceutical companies
Series B · $2.7B · 2026-05
$2.7B - CardiaTec
Uses AI and large-scale multi-omics data to discover new therapies for cardiovascular disease
Seed · $7M · 2024-09
$7M
Other / unspecified
BusinessLatest roundTotal raisedDate- Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M - Field-S
Personalized herbal health formulation SaaS based on genomic and biomarker data: LLM + reinforcement learning generate personalized functional formulas from a library of 500+ plant extracts, iterated on users' daily feedback.
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 22 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.